Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Article Information
vol. 36 no. 9 2543-2550
PubMed
Published By
Print ISSN
Online ISSN
History
- Received October 1, 2012
- Accepted February 8, 2013
- Published in print August 22, 2013.
- Published online ahead of print March 27, 2013.
Article Versions
- Previous version (March 27, 2013 - 12:32).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Author Information
- Bo Ahrén, MD, PHD1⇑,
- Aniceto Leguizamo Dimas, MD2,
- Patrick Miossec, MD3,
- Stéphane Saubadu, MD3 and
- Ronnie Aronson, MD, FRCPC, FACE4
- 1Lund University, Lund, Sweden
- 2Centro de Investigación Clínica del Pacifico, Acapulco, Mexico
- 3Sanofi Global R&D, Paris, France
- 4LMC Diabetes and Endocrinology, Toronto, Canada
- Corresponding author: Bo Ahrén, bo.ahren{at}med.lu.se.
Statistics from Altmetric.com
Article usage
In this Issue
September 2013, 36(9)
Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
